Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;2(3):450-5.
doi: 10.1177/193229680800200314.

Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates

David Kerr  1 , John Morton, Caroline Whately-Smith, Joan Everett, Joe P Begley
Affiliations

Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates

David Kerr et al. J Diabetes Sci Technol. 2008 May.

Abstract

Background: Rapid-acting analog insulin is used increasingly for continuous subcutaneous insulin infusion therapy (CSII). As the choice of insulin may be a determinant of catheter occlusion, we compared rates of early and late occlusion of a standard CSII catheter with three insulin analogs in a laboratory-based setting.

Methods: Twenty-four pumps were used for the study. Each insulin analog (glulisine, lispro, and aspart) was assigned to eight pumps in a randomized order for each of nine runs of 5-day duration. Pumps were primed to receive a basal dose of 0.1 IU/h with a bolus dose of 2 IU given three times each day. Pumps were placed in an incubator to maintain temperature in the range of 32 to 36 degrees C.

Results: Over the entire study period, there were 48 occlusions. Early occlusions (within 72 hours) occurred during five of the nine runs with no evidence of any difference between insulins (p = .27); there were no occlusions before 48 hours. Over the whole of the 5-day infusion period, the probabilities of overall occlusion for each insulin were 40.9% [28 to 55%, 95% confidence interval (CI)] for glulisine, 9.2% (4 to 19.5%, 95% CI) for aspart, and 15.7% (8.1 to 28.1%, 95% CI) for lispro. All occlusions, except for three, occurred during a bolus infusion.

Conclusions: During CSII under laboratory conditions, early catheter occlusions (within 72 hours) are rare and independent of the choice of insulin analog. For patients using insulin pump therapy, the importance of catheter change within 72 hours should be emphasized irrespective of the insulin used. Beyond 72 hours, the risk of occlusion differs between insulins, being more common with glulisine.

Keywords: CSII; analogs; insulin; occlusions; temperature.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Estimate of probability of having no occlusion related to time (hours).
Figure 2.
Figure 2.
Estimate of probability of having no occlusion related to number of boluses
See this image and copyright information in PMC

References

    1. NICE Technology Appraisal Guidance No. 57: Guidance on the use of continuous subcutaneous insulin infusion for diabetes. National Institute for Clinical Excellence. 2003 Feb
    1. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber TR. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005;165(12):1337–1344. - PubMed
    1. Medtronic Diabetes UK [homepage on the Internet] Watford UK: Medtronic MiniMed, Inc.; 2008. [cited 2007 September 30]. Effective infusion site management. Available from: http://www.medtronic-diabetes.co.uk/pdf/MedtronicUK/
    1. Guilhem I, Leguerrier AM, Lecordier F, Poirier JY, Maugendre D. Technical risks with subcutaneous insulin infusion. Diabetes Metab. 2006;32(3):279–284. - PubMed
    1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26(4):1079–1087. - PubMed